Pulmonaryhypertensionnews.com1h
Adempas helps lower risk in PAH patients, newer risk model confirms
A possibly more precise risk model showed Adempas helped PAH patients at intermediate risk of death arrive at more favorable ...
Pulmonaryhypertensionnews.com5d
Winrevair regimen balances efficacy, safety in PAH: Analysis
The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...
Pulmonaryhypertensionnews.com9d
Weight-based Uptravi dosing appropriate for PAH children: Study
A body weight-adjusted regimen of Uptravi dosing for children and adolescents with PAH was deemed appropriate, according to a ...
Pulmonaryhypertensionnews.com12d
Phase 2 trial of tiprelestat for PAH receives FDA advice
The U.S. FDA has provided advice for Tiakis Biotech's Phase 2 clinical trial of tiprelestat for pulmonary arterial ...
Pulmonaryhypertensionnews.com13d
Alivegen’s ALG-801 named FDA orphan drug for PAH
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen ’s experimental ...
Pulmonaryhypertensionnews.com9d
PH can impose physical restrictions, but don’t limit yourself
Living with PH, it's easy to focus on what we can't do instead of what we can. Columnist Colleen Steele's advice? Don't limit ...
Pulmonaryhypertensionnews.com14d
How I struggle to manage chronic pain during the holidays
Are you managing chronic pain alongside pulmonary hypertension (PH)? Did it disrupt your holiday plans? If you answered yes, you’re not alone. Many folks in the PH and broader rare disease communities ...